An update on Stevens-Johnson syndrome and toxic epidermal necrolysis in children

Current Opinion in Pediatrics

Volumn 21, Issue 4, 2009, Pages 505-510

  Koh, Mark Jean Aan ^a   Tay, Yong Kwang ^a  

^a CHANGI GENERAL HOSPITAL   (Singapore)

Author keywords

Corticosteroids; Intravenous immunoglobulins; Stevens Johnson syndrome; Toxic epidermal necrolysis

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; DEXAMETHASONE; FAS ANTIGEN; FAS LIGAND; GRANULYSIN; GRANZYME B; HLA ANTIGEN; IMMUNOGLOBULIN; INFLIXIMAB; METHYLPREDNISOLONE; PERFORIN; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; CONSERVATIVE TREATMENT; CORTICOSTEROID THERAPY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESEARCH; GENETIC SUSCEPTIBILITY; HUMAN; KERATINOCYTE; LOW DRUG DOSE; NATURAL KILLER CELL; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; SINGLE DRUG DOSE; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; DERMATOLOGIC AGENTS; EPIDERMAL NECROLYSIS, TOXIC; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULINS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; PLASMAPHERESIS; SKIN CARE; STEVENS-JOHNSON SYNDROME; TREATMENT OUTCOME;

EID: 68949187792     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOP.0b013e32832d1fef     Document Type: Review

References (63)

1. Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multi-forme. Arch Dermatol 1993; 129:92-96.
2. Letko GN, Papaliodis DN, Papaliodis GN, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol 2005; 94:419-436.
3. Forman R, Koren G, Shear NH. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years' experience. Drug Safety 2002; 25:965-972.
4. Leaute-Labreze C, Lamireau T, Chawki D, et al. Diagnosis, classification, and management of erythema multiforme and Stevens-Johnson syndrome. Arch Dis Child 2000; 83:347-352.
5. Metry DW, Jung P, Levy ML. Use of intravenous immunoglobulin in children with Stevens-Johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature. Pediatrics 2003; 112:1430-1436.
6. Tay YK, Huff C, Weston WL. Mycoplasma pneumoniae infection is associated with Stevens-Johnson syndrome, not erythema multiforme (von Hebra). J Am Acad Dermatol 1996; 35:757-760.
7. Chung WH, Hung SI, Hong HS, etal. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428:486.
8. Lonjou C, Borot N, Sekula P, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008; 18:99-107.
9. Kaniwa N, Saito Y, Aihara M, et al. HLA-B locus in Japanese patients with antiepileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2008; 9:1617-1622.
10. Ferrell PB Jr, McLeod HL Carbamazepine, HLA-B* 1502 and risk of Stevens- Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics 2008; 9:1543-1546.
11. Abe R, Shimizu T, Shibaki A, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am J Pathol 2003; 162:1515-1520.
12. Nagata S. Apoptosis by death factor. Cell 1997; 88:355-365.
13. Murata J, Abe R, Shimizu H. Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment. J Allergy Clin Immunol 2008; 122:992-1000.
14. Abe R. Toxic epidermal necrolysis and Stevens-Johnson syndrome: soluble Fas ligand involvement in the pathomechanisms of these diseases. J Dermatol Sci 2008; 52:151-159.
15. Lan CC, Wu CS, Tsai PC, Chen GS. Diagnostic role of soluble Fas ligand secretion by peripheral blood mononuclear cells from patients with previous drug-induced blistering diseases: a pilot study. Acta Derm Venereol 2006; 86:215-218.
16. Ueta M, Sotozono C, Inatomi T, et al. Association of Fas ligand gene polymorphism with Stevens-Johnson syndrome. Br J Ophthalmol 2008; 92:989-991.
17. Nassif A, Bensussan A, Boumsell L, etal. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol 2004; 114:1209-1215.
18. Posadas SJ, Padial A, Torres M, etal. Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J Allergy Clin Immunol 2002; 109:155-161.
19. Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator of disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 2008; 14:1343-1350.
20. Deng A, Chen S, Lyu SC, et al. Granulysin, a cytolytic molecule, is also a chemoattractant and proinflammatory activator. J Immunol 2005; 1 74:5243-5248.
21. Caproni M, Torchia D, Schincaglia E, et al. Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis. Br J Dermatol 2006; 155:722-728.
22. Correia O, Delgado L, Barbosa IL, et al. Increased interleukin 10, tumor necrosis factor alpha, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis. J Am Acad Dermatol 2002; 47:58-62.
23. Arnold R, Seifert M, Asadullah K, Volk HD. Crosstalk between keratinocytes and T lymphocytes via Fas/Fas ligand interaction: modulation by cytokines. J Immunol 1999; 162:7140-7147.
24. Caproni M, Torchia D, Volpi W, et al. Expression of matrix metalloproteinases 2, 9 and 11 in erythema multiforme: immunohistochemical comparison with Stevens-Johnson syndrome/toxic epidermal necrolysis. Br J Dermatol 2008; 158:1163-1166.
25. Pereira FA, Mudfil AV, Rosmarin DM. Toxic epidermal necrolysis. J Am Acad Dermatol 2007; 56:181-200.
26. Kano Y, Hirahara K, Mitsuyama Y, etal. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy 2007; 62:1439-1444.
27. Bastuji-Garin S, Fouchard N, Berocchi M, et al. SCORTEN: a severity of illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115:149-153.
28. Guegan S, Bastuji-Garin S, Poszepczynska-Guigne E, et al. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol 2006; 126:272-276.
29. Garcia-Doval I, LeCleach L, Bocquet H, etal. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 2000; 136:323-337.
30. Fromowitz JS, Ramos-Caro FA, Flowers FP. Practical guidelines for the management of toxic epidermal necrolysis and Stevens-Johnson syndrome. Int J Dermatol 2007; 46:1092-1094.
31. Mayes T, Gottschlich M, Khoury J, et al. Energy requirements of pediatric patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Nutr Clin Pract 2008; 23:547-550.
32. Abood GJ, Nickoloff BJ, Gamelli RL Treatment strategies in toxic epidermal necrolysis: where are we at? J Burn Care Res 2008; 29:269-276.
33. Asz J, Asz D, Moushey R, et al. Treatment of toxic epidermal necrolysis in a pediatric patient with a nanocrystalline silver dressing. J Pediatr Surg 2006; 41:e9-e12.
34. Huang SH, Wu SH, Sun IF, et al. AQUACEL Ag in the treatment of toxic epidermal necrolysis (TEN). Burns 2008; 34:63-66.
35. Pfurtscheller K, Zobel G, Roedl S, Trop M. Use of Suprathel dressing in a young infant with TEN. Pediatr Dermatol 2008; 25:541-543.
36. Boorboor P, Vogt PM, Bechara FG, et al. Toxic epidermal necrolysis: use of Biobrane or skin coverage reduces pain, improves mobilisation and decreases infection in elderly patients. Burns 2008; 34:487-492.
37. Yip LW, Thong BY, Lim J, et al. Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an Asian series. Allergy 2007; 62:527-531.
38. Yip LW, Thong BY, Tan AW, et al. High-dose intravenous immunoglobulin in the treatment of toxic epidermal necrolysis: a study of ocular benefits. Eye 2005; 19:846-853.
39. Gregory DG. The ophthalmologic management of acute Stevens-Johnson syndrome. Ocul Surf 2008; 6:87-95.
40. Schneck J, Fagot JP, Sekula P, et al. Effects of treatment on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR study. J Am Acad Dermatol 2008; 58:33-40.
41. Kardaun SH, Jonkman MF. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol 2007; 87:144-148.
42. Yamane Y, Aihara M, Ikezawa Z. Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan from 2000 to 2006. Allergol Int 2007; 56:419-425.
43. Tripathi A, Ditto AM, Grammer LC, et al. Corticosteroid therapy in an additional 13 cases of Stevens-Johnson syndrome: a total series of 67 cases. Allergy Asthma Proc 2000; 21:101-105.
44. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockage of CD95 with human intravenous immunoglobulin. Science 1998; 282:490-493.
45. Parquet P, Kaveri S, Jacob E, et al. Skin immunoglobulin deposition following intravenous immunoglobulin therapy in toxic epidermal necrolysis. Exp Dermatol 2006; 15:381-386.
46. French LE, Trent JT, Kerdel FA. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding. Int Immunopharmacol 2006; 6:543-549.
47. Mittmann N, Chan B, Knowles S, et al. Intravenous immunoglobulin use in patients with toxic epidermal necrolysis and Stevens-Johnson syndrome. Am J Clin Dermatol 2006; 7:359-368.
48. Bachot N, Revuz J, Rojeau JC. Intravenous immunoglobulin for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncom-parative study showing no benefit on mortality or progression. Arch Dermatol 2003; 139:33-36.
49. Shortt R, Gomez M, Mittman N, Cartotto R. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil 2004; 25:246-255.
50. Brown JM, Silver GM, Halerz M, et al. Toxic epidermal necrolysis: does immunoglobulin make a difference? J Burn Care Rehabil 2004; 25:81-88.
51. Yeung CK, Lam LK, Chan HH. The timing of intravenous immunoglobulin therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis. Clin Exp Dermatol 2005; 30:578-602.
52. Prins C, Kerdel FA, Padilla RS, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003; 139:85-86.
53. Morici MV, Galen WK, Shetty AK, et al. Intravenous immunoglobulin therapy for children with Stevens-Johnson syndrome. J Rheumatol 2000; 27:2494-2497.
54. Tristani-Firouzi P, Petersen MJ, Saffle JR, et al. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol 2002; 47:548-552.
55. Mangla K, Rastogi S, Goyal P, et al. Efficacy of low dose intravenous immunoglobulins in children with toxic epidermal necrolysis: an open uncontrolled study. Indian J Dermatol Venereol Leprol 2005; 71:398-400.
56. Lam NS, Yang YH, Wang LC, et al. Clinical characteristics of childhood erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in Taiwanese children. J Microbiol Immunol Infect 2004; 37:366-370.
57. Koh MJA, Tay YK. A 5-year review of Stevens-Johnson syndrome and toxic epidermal necrolysis in Asian children [poster]. In: 34th Annual Meeting of Society for Pediatric Dermatology; 9-12 July 2008; Snowbird, UT.
58. Arevalo JM, Lorente JA, Gonzalez-Herrada C, Jimenez-Reyes J. Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma 2000; 48:473-478.
59. Aihara Y, Ito R, Ito S, et al. Toxic epidermal necrolysis in a child successfully treated with cyclosporin A and methylprednisolone. Pediatr Int 2007; 49:659-662.
60. Wolkenstein P, Latarjet J, Roujeau JC, et al. Randomized comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998; 352:1586-1589.
61. Fischer M, Fiedler E, Marsch WC, Wohlrab J. Antitumour necrosis factor-a antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol 2002; 146:707-708.
62. Hunger RE, HunzikerT, Buettiker U, etal. Rapid resolution of toxic epidermal necrolysis with anti-TNF-a treatment. J Allergy Clin Immunol 2005; 116:923-924.
63. Yamada H, Takamori K. Status of plasmapheresis for the treatment of toxic epidermal necrolysis in Japan. Ther Apher Dial 2008; 12:355-359.